EFFICACY AND SAFETY OF ORAL CYCLOSPORIN IN TREATMENT OF PYODERMA GANGRENOSUM

Dr Priya kariya, Dr Sneha patel, Dr Krina patel

Abstract


INTRODUCTION: Pyoderma gangrenosum (PG) is an idiopathic, non-infectious ulcerating disorder predominantly involving skin, with primarily neutrophilic inflammatory infiltrate. The mainstay of therapy for PG has been high-dose corticosteroids but systemic agents such as cyclophosphamide, cyclosporine or azathioprine can be used.

AIMS: To evaluate efficacy and safety of oral cyclosporine in patients with pyoderma gangrenosum.

 

MATERIALS AND METHOD: A retrospective study of patients presenting with pyoderma gangrenosum from February 2014 to February 2018 was carried out. All patients were given oral cyclosporine 3 mg/kg/day for minimum 6 weeks to maximum 12 weeks as per requirement. At the end of therapy patients were classified according to response and reduction ulcer area score.

RESULTS: Ulcer area in each patient reduced above 60% with minimal side effects after giving cyclosporine for 12 weeks. Out of 27 patients, 12 had excellent response (>90%). While 10 patients had good response (70-90 %) and 5 had good response (50-70%).

CONCLUSION:  This study shows that systemic low dose cyclosporine is an effective and safe treatment option available for pyoderma gangrenosum.


Keywords


Cyclosporin, Pyoderma gangrenosum, IgA gammopathy

Full Text:

PDF

References


Saumya P, Aparajita G. “Neutrophillic Dermatosis”. In: S.Sacchidanand, IADVL Textbook of Dermatology,4th edition. Bhalani publications 2015:2(34):1248-1280

Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, Jr., White WL, Callen JP. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission: case review of 86 patients from 2 institutions. Medicine. 2000;79(1):37–46.

Mamta A, Joshi A, Gulati A, Bansal R, Pathak VP. Localized granulomatous pyoderma gangrenosum. Indian J Dermatol Venereol Leprol 2003;69 Suppl S1:80-2.

Bhutani T, Lee CS, Koo JYM. Cyclosporine. In, comprehensive dermatologic drug therapy ed. Wolverton S, Elsevier pub.2013, p:199 -211.Nagaraju U, Sundar PK, Agrawal P,Raju BP, Kumar .

Autologous Platlet rich Fibrin Matrix in Non-healing Trophic Ulcer in Patients with Hansen’s Disease . J Cutan Aesthet Surg.2017;10(1):3-7.dol:10.4103.

Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacumm-assisted closure with advanced moist wound therapy in treatment of diabetic foot ulcers: A multicenter randomized controlled trial. Diabetes Care. 2008:31:631-6.

Azizan NZ, Gangaram HB, Hussein SH.Med J Malaysia. 2008 Mar; 63(1):51-4

Powell FC, Su WPD et al. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34: 395-409.

Riyaz N, Mary V, Sasidharanpillai S, Roshin RA, Snigdha O, Latheef EN, Rahima S, Bindu V, Anupama RN, Sureshan DN, Sherjeena PV. Pyoderma gangrenosum: A clinico-epidemiological study. Indian J Dermatol VenereolLeprol2017;83:33-9

Treatment of pyoderma gangrenosum BMJ 2015; 350 , BMJ 2015;350:h3175

Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of Pyoderma Gangrenosum With Cyclosporine. Arch Dermatol. 1992;128(8):1060–1064.

Zumdick M, Goerz G, Schuppe HC, Milde P, Ruzicka T. Niedrig dosierte Cyclosporin-A-Therapie bei Pyoderma gangraenosum. Erfahrungen bei 6 Patienten [Low dosage cyclosporin A therapy in pyoderma gangrenosum. Experiences with 6 patients]. Hautarzt. 1995;46(10):697–701.


Refbacks

  • There are currently no refbacks.